In osteoporotic ovariectomized rats, bone-targeting PLGA-derived lipid treatment delivery system decreases bone loss

The distribution of anti-osteoporotic medications at the right dose has proven difficult due to the lack of safety, efficacy, and specificity. In our research, bone-specific polyaspartic acid Asp) 8-DNPs were added to cathepsin K inhibitor loaded poly derived lipid hybrid nanoparticles to cure osteoporosis. DNPs shown their affinity for binding to hydroxyapatite and were successful in releasing cathepsin K inhibitors over the course of up to 5 days. The tartrate-resistant acid phosphatase activity and resorption-related genes in osteoclasts were drastically reduced by cathepsin K inhibitor loaded Asp 8-DNPs. The tibia and femur of animals showed high levels of Asp 8-DNP accumulation, as well as increased trabecular bone mass and more organised three-dimensional architecture in osteoporotic rat models. Herein, the bone targeted drug delivery system show its potential in treatment of osteoporosis

Keywords

Bone-targeting; Polyaspartic acid peptides; Drug delivery system; Osteoporosis; Anti-osteoporosis drug

மறுப்பு: இந்த சுருக்கமானது செயற்கை நுண்ணறிவு கருவிகளைப் பயன்படுத்தி மொழிபெயர்க்கப்பட்டது மற்றும் இன்னும் மதிப்பாய்வு செய்யப்படவில்லை அல்லது சரிபார்க்கப்படவில்லை

மூலக்கூறு நொதியியல் மற்றும் மருந்து இலக்குகள்

குறியிடப்பட்டது

இந்தப் பக்கத்தைப் பகிரவும்

சுருக்கம்

In osteoporotic ovariectomized rats, bone-targeting PLGA-derived lipid treatment delivery system decreases bone loss